Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 74 of 182 for:    ERYTHROMYCIN

Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02251132
Recruitment Status : Completed
First Posted : September 29, 2014
Last Update Posted : September 29, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The objective of this study is to establish the tipranavir-ritonavir steady-state dose-exposure relationships when administered on a b.i.d. dosing regimen; to determine the effects of tipranavir (TPV) and ritonavir (RTV) on cytochrome P-450 (CYP3A4) activity; to establish the dependency of the TPV M1 metabolite on RTV co-administration. Additionally, the short-term safety and tolerance of this drug combination will be evaluated.

Condition or disease Intervention/treatment Phase
Healthy Drug: TPV low 1 Drug: TPV low 2 Drug: TPV medium Drug: TPV high 1 Drug: TPV high 2 Drug: RTV low Drug: Ritonavir high Drug: Radiolabelled erythromycin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 113 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Parallel Group, Multiple-dose Investigation of the Pharmacokinetics of Tipranavir Soft Elastic Capsules SEDDS and Ritonavir Soft Gel Capsules and Their Effects on Cytochrome P-450 (3A4) Activity in Normal Healthy Volunteers
Study Start Date : October 2000
Actual Primary Completion Date : December 2000

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TPV/RTV Low 1 Drug: TPV low 1
Drug: Ritonavir high
Drug: Radiolabelled erythromycin
Experimental: TPV/RTV Low 2 Drug: TPV low 2
Drug: RTV low
Drug: Radiolabelled erythromycin
Experimental: TPV/RTV Low 3 Drug: TPV low 2
Drug: Ritonavir high
Drug: Radiolabelled erythromycin
Experimental: TPV/RTV Medium 1 Drug: TPV medium
Drug: RTV low
Drug: Radiolabelled erythromycin
Experimental: TPV/RTV Medium 2 Drug: TPV medium
Drug: Ritonavir high
Drug: Radiolabelled erythromycin
Experimental: TPV/RTV High 1 Drug: TPV high 1
Drug: RTV low
Drug: Radiolabelled erythromycin
Experimental: TPV/RTV High 2 Drug: TPV high 1
Drug: Ritonavir high
Drug: Radiolabelled erythromycin
Experimental: TPV/RTV High 3 Drug: TPV high 2
Drug: Ritonavir high
Drug: Radiolabelled erythromycin



Primary Outcome Measures :
  1. Trough plasma concentration at steady state (Cmin,ss) [ Time Frame: up to 24 hours ]
  2. Maximum plasma concentration at steady state (Cmax,ss) [ Time Frame: up to 24 hours ]
  3. Time of maximum concentration (tmax) [ Time Frame: up to 24 hours ]
  4. Area under the plasma concentration time curve from 0 to 12 hours (AUC0-12) [ Time Frame: up to 12 hours ]

Secondary Outcome Measures :
  1. Oral clearance (Cl/F) [ Time Frame: up to 24 hours ]
  2. Apparent terminal half life (t1/2) [ Time Frame: up to 24 hours ]
  3. Percent of erythromycin metabolized per hour [ Time Frame: up to 24 hours ]
    Erythromycin breath test (ERMBT)

  4. Number of subjects with clinically significant findings in laboratory tests [ Time Frame: up to 32 days ]
  5. Number of subjects with adverse events [ Time Frame: up to 32 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female between 18 and 75 years of age inclusive
  • Female subjects of child-bearing potential are required to use a barrier contraceptive method for at least 3 months prior to administration of study medication, during study medication administration and for 30 days after the end of the study
  • Ability to swallow numerous large capsules without difficulty
  • A body mass index (BMI) between 19 and 29 kg/m2
  • Signed informed consent prior to trial participation
  • Reasonable probability for completion of the study
  • Acceptable screening laboratory values that indicate adequate baseline organ function are required at the time of screening. Laboratory values are considered to be acceptable if severity is no higher than Grade 1 based on the AIDS Clinical Trials Group (ACTG) Grading Scale. All laboratory values > Grade 1 are subject to approval by the BIPI clinical monitor
  • Acceptable medical history, physical examination, electrocardiogram, and chest X-ray are required prior to entering the treatment phase of the study
  • Willingness to abstain from alcohol for 48 hours prior to study Day 0 and abstain from alcohol for the duration of the study
  • Willingness to abstain from ingesting grapefruit or grapefruit juice for the duration of the study
  • Urine drug screen negative for drugs of abuse
  • Negative HIV serology
  • Negative for Hepatitis B surface antigen and Hepatitis C antibody

Exclusion Criteria:

  • Female subjects who:

    • have a positive serum pregnancy test at Visits 1 or 2 OR
    • are breastfeeding
  • Receipt of any other investigational medicine for 30 days prior to Day 0
  • Receipt of any known enzyme altering drug for 30 days prior to Day 0, grapefruit and grapefruit juice within 15 days prior to Day 0 and antibiotics within 10 days prior to Day 0
  • Excessive cigarette smoking, defined as greater than 10 cigarettes per day
  • Blood or plasma donation within 30 days prior to Day 0
  • Subjects with a seated systolic blood pressure either < 100 mg Hg or > 150 mm Hg; resting heart rate either < 50 beats/min or > 90 beats/min
  • Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering tipranavir or ritonavir to the subject
  • Subjects who have had an acute illness within 2 weeks prior to Day 0
  • Subjects who are currently taking any over-the-counter drug within 7 days prior to Day 0, or who are currently taking any prescription drug that, in the opinion of the investigator in consultation with the BIPI medical monitor and pharmacokineticist, might interfere with either the absorption, distribution or metabolism of the test substances
  • Hypersensitivity to tipranavir, ritonavir or sulfonamide containing drugs
  • Evidence of active substance abuse that, in the investigator's opinion, could affect study adherence

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02251132     History of Changes
Other Study ID Numbers: 1182.5
First Posted: September 29, 2014    Key Record Dates
Last Update Posted: September 29, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Erythromycin
Ritonavir
Tipranavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Anti-Bacterial Agents
Gastrointestinal Agents
Protein Synthesis Inhibitors